To find out if bNAbs, VRC07-523LS and PGT121.414.LS, are safe for administration with ART. To evaluate if the bNAbs are effective at keeping HIV from reproducing. It is necessary to stop taking ART after receiving the bNAbs or placebos for bNAbs. This is referred to as an ATI (analytical treatment interruption).
This study wants to see if gut problems are worse in HIV+ men that have sex with men that have metabolic syndrome compared those without metabolic syndrome.
This study will look at how well an injectable treatment works for people with detectable levels of HIV who are taking oral antiretroviral therapy (ART). This study will also check if the treatment is safe, how long it lasts, and ask about people’s experience.
Study will look at the effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. Study will also look at whether effects of tesamorelin are maintained after stopping treatment.
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis ...
This study wants to see if gut problems are worse in men with and without HIV that have sex with men who have metabolic syndrome compared to those without metabolic syndrome. We are looking for men that do not have HIV.
The primary objective of the study is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing standard of care in virologically suppressed PWH at Week 48.